Results 41 to 50 of about 7,985,327 (252)

Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report [PDF]

, 2011
Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Ossaden Abdelmalek, Kaoutar Znati, El Mrabet Fatima, Amarti Affaf, Yousra Akasbi, Brahmi Sami, Abdelmalek Ossaden, Ibrahimi Adil, Khalid Maazaz, Khalid Ait Taleb, Taleb Khalid, Sami Aziz Brahmi, Affaf Amarti, Touyar Anas, Akasbi Yousra, Znati Kaoutar, El Mesbahi Omar, Siham Tizniti, Omar El Mesbahi, Anas Touyar, Adil Ibrahimi, Maazaz Khalid, Tizniti Siham, Fatima Zahra El Mrabet   +23 more
core   +2 more sources

The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study

Frontiers in Immunology
BackgroundFor esophageal squamous cell carcinoma(ESCC), neoadjuvant chemoimmunotherapy (nICT) constitutes an innovative therapeutic strategy. However, The relationship between its short-term efficacy and long-term prognosis requires further clarification.
Shuhan Xie, Shuhan Xie, Shuhan Xie, Shuhan Xie, Shijie Huang, Zilu Tang, Hai Zhang, Jinxin Xu, Sunkui Ke, Jinbiao Xie, Rongyu Xu, Ying Chen, Zhinuan Hong, Zhinuan Hong, Zhinuan Hong, Zhinuan Hong, Mingqiang Kang, Mingqiang Kang, Mingqiang Kang, Mingqiang Kang   +19 more
doaj   +1 more source

Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic micro‐inflammation in patients with end‐stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small‐molecule clearance, its ability to remove medium‐to‐large uremic toxins—the primary catalysts of systemic ...
Hongwei Zuo, Weisi Dai, Jie Mao, Mei Ye, Xingshan Lu, Xiaocui Zhang   +5 more
wiley   +1 more source

Summary of pathological complete response rates in different subsets.

, 2019
Summary of pathological complete response rates in different subsets.
Sujata Patil (674937), Geoffrey Lindeman (62068), Mustafa Khasraw (6335354), Andrea Muscat (267150), Ian Collins (421015), David Ashley (143624), Violet Mukaro (6335342), Linda West (6335345), Wei Shi (68167), Sally Baron-Hay (6335351), Yang Liao (292677), David Chisanga (6335348), Caitlin Murphy (6335339)   +12 more
core   +1 more source

Impact of Sarcopenia on Treatment Outcomes and Toxicity in Locally Advanced Rectal Cancer

Medicina
Background and Objectives: Sarcopenia, a condition characterized by muscle mass loss, is prevalent in up to 68% of rectal cancer patients and has been described as a negative prognostic factor, impacting overall survival and tumor response.
Sebastian Curcean, Alexandra Gherman, Alexandru Tipcu, Zsolt Fekete, Alina-Simona Muntean, Andra Curcean, Rares Craciun, Stefan Stanciu, Alexandru Irimie   +8 more
doaj   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

Gene and microRNA expression predictive of tumour response in patients treated with preoperative chemoradiotherapy for rectal cancer [PDF]

, 2013
Background Preoperative chemoradiotherapy (pCRT) followed by surgery is the standard treatment for locally advanced rectal cancer (LARC). However, the response to pCRT is not uniform, and there is no effective method to predict tumour response to pCRT ...
Maretto, I
core  

Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer

World Journal of Surgical Oncology, 2020
Background Nonoperative management after neoadjuvant treatment in low rectal cancer enables organ preservation and avoids surgical morbidity. Our aim is to compare oncological outcomes in patients with clinical complete response in watch and wait ...
Mariana F. Coraglio, Martin A. Eleta, Mirta R. Kujaruk, Javier H. Oviedo, Enrique L. Roca, Guillermo A. Masciangioli, Guillermo Mendez, Ilma S. Iseas   +7 more
doaj   +1 more source

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report

Frontiers in Oncology, 2020
Treatment options as second-line therapy for advanced ureteral carcinoma are limited, and patients experiencing recurrence after first-line cisplatin-based chemotherapy have a poor prognosis.
Daiki Ikarashi, Daiki Ikarashi, Daiki Ikarashi, Shigehisa Kitano, Kazuyuki Ishida, Tetsuya Nakatsura, Hitoshi Shimodate, Takashi Tsuyukubo, Daichi Tamura, Renpei Kato, Tamotsu Sugai, Wataru Obara   +11 more
doaj   +1 more source

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma

Medicina, 2022
Background and Objectives: Complete pathological response after ipilimumab and nivolumab combination therapy in a patient with intermediate prognosis renal cell carcinoma is an uncommon finding.
Hana Studentova, Anezka Zemankova, Martina Spisarova, Daniela Skanderova, Zbynek Tudos, Bohuslav Melichar, Vladimir Student   +6 more
doaj   +1 more source